share_log

Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11

Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11

Evercore ISI集团将健康催化剂上调至跑赢大盘,将目标股价上调至11美元
Benzinga ·  01/03 08:06

Evercore ISI Group analyst Elizabeth Anderson upgrades Health Catalyst (NASDAQ:HCAT) from In-Line to Outperform and raises the price target from $9 to $11.

Evercore ISI集团分析师伊丽莎白·安德森将Health Catalyst(纳斯达克股票代码:HCAT)从In-Line上调至跑赢大盘,并将目标股价从9美元上调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发